PRELUDE CAPITAL MANAGEMENT, LLC
Position in ACRV — Acrivon Therapeutics, Inc.
CIK 1387508
NEW YORK, NY
Position in ACRV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$42,746
+$9,366 QoQ
Shares Held
24,015
0.0% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#22
of 46 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in ACRV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRELUDE CAPITAL MANAGEMENT, LLC holds $41,687,806 across 71 Biotechnology names. ACRV ranks #66 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | APGE |
Apogee Therapeutics, Inc.
|
58,590 | $7,776,650 | |
| 2 | TECH |
BIO-TECHNE Corp
|
91,696 | $6,478,322 | |
| 3 | PGEN |
Precigen, Inc.
|
882,267 | $5,028,921 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
113,104 | $4,002,750 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
10,997 | $2,059,518 | |
| 6 | QURE |
uniQure N.V.
|
32,229 | $1,484,467 | |
| 7 | MDXG |
Mimedx Group, Inc.
|
215,239 | $828,670 | |
| 8 | CGON |
CG Oncology, Inc.
|
10,811 | $768,121 |
All Filings in ACRV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $42,746 | 24,015 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $33,380 | 24,015 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $115,716 | 48,015 | Shares | Other | 2026-02-17 | |
| 2025-03-31 | $26,526 | 13,067 | Shares | Other | 2025-05-15 | |
| 2024-09-30 | $264,089 | 37,727 | Shares | Other | 2024-11-14 | |
| 2024-03-31 | $92,950 | 13,000 | Shares | Other | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||